Shinya Watanabe | Neuroscience | Best Research Award

Assist. Prof. Dr. Shinya Watanabe | Neuroscience | Best Research Award

University of Tsukuba | Japan 

Author Profile

Scopus

Orcid

Early Academic Pursuits 🎓

Dr. Shinya Watanabe’s academic journey began at Chiba University’s Department of Pharmaceutical Sciences. However, driven by a passion for medicine, he transitioned to the University of Tsukuba, earning a Bachelor’s degree in Medicine in 2005 and later a Ph.D. in Medicine in 2015. His diverse educational pursuits also include a specialized program in Medical Innovation Strategy at Chiba University, reflecting his commitment to integrating clinical expertise with innovative healthcare solutions.

Professional Endeavors 🩺

Dr. Watanabe’s illustrious medical career spans over two decades, marked by extensive hands-on experience across several leading hospitals in Japan. Starting as a resident at Tsukuba University Hospital, he later specialized as a neurosurgeon in institutions like Hitachi General Hospital and Tsukuba Medical Center. His tenure with the Pharmaceuticals and Medical Devices Agency (PMDA) between 2017 and 2020 saw him influencing drug, device, and regenerative medicine reviews, underscoring his role as a key figure in Japan’s medical regulatory landscape. Currently, he serves as a Lecturer at the University of Tsukuba’s Faculty of Medicine, contributing to both clinical practice and medical education.

Contributions and Research Focus 🔬

Dr. Watanabe’s research spans a variety of critical areas, including neurotrauma, cancer treatment, and dementia. His expertise has been certified by prestigious bodies such as the Japan Neurosurgical Society and the Japanese Society of Dementia. A thought leader in his field, Dr. Watanabe has actively developed innovative treatments, such as headache management techniques, and remains a sought-after expert in advancing medical technology and therapeutic strategies.

Accolades and Recognition 🏆

Dr. Watanabe’s exceptional contributions have been celebrated with numerous awards, such as the 12th Nose Award and the Research Encouragement Award from the Japanese Society for Diencephalo-Pituitary Tumors. In 2020, his groundbreaking interdisciplinary work earned him the Joyo Bank Award, highlighting his ability to bridge clinical practice with innovative technologies.

Impact and Influence 🌍

Through his extensive clinical and academic roles, Dr. Watanabe has shaped the practice of neurosurgery and medical device innovation in Japan. His contributions to the PMDA and ARO Council have had far-reaching effects, ensuring that healthcare products meet rigorous safety and efficacy standards. He has also inspired future generations of medical professionals through his dedication to education at the University of Tsukuba.

Legacy and Future Contributions 🌟

Dr. Watanabe’s legacy lies in his ability to blend clinical precision with innovation. As a pioneer in interdisciplinary research, he continues to push the boundaries of medical science, ensuring a brighter future for patients worldwide. His ongoing contributions to neuroscience, cancer treatment, and dementia care are set to redefine the standards of modern medicine, establishing him as a beacon of excellence in healthcare. With a career characterized by unwavering dedication and transformative achievements, Assist. Prof. Dr. Shinya Watanabe embodies the spirit of medical innovation and compassion.

 

Publications


📄"A Case of Idiopathic Intracranial Hypertension Complicated with both Infratentorial and Supratentorial Cortical Superficial Siderosis: Novel Imaging Findings on Intravoxel Incoherent Motion Magnetic Resonance Imaging Offering Clues to Pathophysiology"

  • Author: Watanabe, S.; Shibata, Y.; Ishikawa, E.
  • Journal: Neurology International
  • Year: 2024

📄"A Retrospective Cohort Study of Stereotactic Radiosurgery for Vestibular Schwannomas: Comparison of Two Age Groups (75 Years or Older vs. 65–74 Years)"

  • Author: Watanabe, S.; Yamamoto, M.; Aiyama, H.; Akutsu, H.; Ishikawa, E.
  • Journal: Surgical Neurology International
  • Year: 2024

📄"Recent Status of Phase I Clinical Trials for Brain Tumors: A Regulatory Science Study of Exploratory Efficacy Endpoints"

  • Author: Watanabe, S.; Nonaka, T.; Maeda, M.; Arakawa, Y.; Ishikawa, E.
  • Journal: Therapeutic Innovation and Regulatory Science
  • Year: 2024

📄"Empirical Myoelectric Feature Extraction and Pattern Recognition in Hemiplegic Distal Movement Decoding"

  • Author: Anastasiev, A.; Kadone, H.; Marushima, A.; Matsumaru, Y.; Ishikawa, E.
  • Journal: Bioengineering
  • Year: 2023

📄"Efficacy Endpoints in Phase II Clinical Trials for Meningioma: An Analysis of Recent Clinical Trials"

  • Author: Watanabe, S.; Nonaka, T.; Maeda, M.; Arakawa, Y.; Ishikawa, E.
  • Journal: Therapeutic Innovation and Regulatory Science
  • Year: 2023

 

Inmaculada Gilaberte | Medicine and Dentistry | Best Researcher Award

Dr. Inmaculada Gilaberte | Medicine and Dentistry | Best Researcher Award

FAES Farma | Spain

Author Profile

Scopus

🌱 Early Academic Pursuits

Dr. Inmaculada Gilaberte’s academic journey is rooted in a commitment to excellence and medical advancement. She initially pursued education in clinical research, equipping herself with in-depth knowledge and skills in therapeutic areas such as neuroscience and immunology. Her academic foundation was further strengthened by certifications, including a lecturer certification from the Spanish Quality Register Agency (ANECA), and advanced leadership programs from institutions like Stanford and MIT. These formative experiences shaped her growth mindset, laying the groundwork for a career dedicated to precision, patient-centered care, and effective team collaboration.

💼 Professional Endeavors

Throughout her career, Dr. Gilaberte has held prominent roles in major pharmaceutical companies such as FAES FARMA, Takeda, TiGenix, Roche, and Lilly, with positions spanning from Clinical Research Physician to Director of Clinical Research. She has led various departments, managed global teams, and directed clinical trials across multiple therapeutic areas, including gastroenterology, immunology, cardiology, and pain management. Her strategic guidance has driven several landmark projects forward, including the advancement of microbiome and cell therapies from preclinical to first-in-human trials, demonstrating her expertise in transforming innovative therapies into viable treatment options.

🧬 Contributions and Research Focus

Dr. Gilaberte has made notable contributions to clinical research, particularly in stem cell therapy, immunology, and neuroscience. Her pioneering work on Darvadstrocel, an allogeneic adipose-derived mesenchymal stem cell therapy, led to significant strides in treating perianal fistulas and positioned her as a leader in regenerative medicine. She has been instrumental in launching global clinical trials, developing target product profiles (TPP), and submitting regulatory applications for FDA and EMA approvals. With a robust publication record, including 66 papers indexed in PubMed, she continues to contribute to scientific literature, sharing her findings and advancing the field of biomedicine.

🏆 Accolades and Recognition

Dr. Gilaberte’s excellence has been recognized through numerous awards across her roles in clinical development and leadership. Her achievements include multiple awards for her work in the clinical progression of innovative therapies and successful drug submissions to global regulatory bodies. She has received recognition for her strategic contributions to the Darvadstrocel trials and for advancing neuroscience programs in Alzheimer’s disease. Her leadership has earned her high regard in the industry, with acknowledgments from institutions and colleagues alike.

🌍 Impact and Influence

Dr. Gilaberte’s impact extends beyond her immediate professional roles. Her contributions to clinical science have enhanced treatment options for patients with complex diseases, and her leadership has shaped clinical strategies in multinational pharmaceutical companies. She has also promoted effective collaboration across global, cross-functional teams, fostering a diverse and inclusive work environment that prioritizes patient needs. Her initiatives in regulatory compliance, risk management, and data integration have set new standards for clinical operations, solidifying her influence as a thought leader in her field.

📜 Legacy and Future Contributions

Looking ahead, Dr. Gilaberte’s legacy is one of commitment to advancing patient care through innovation, collaboration, and strategic foresight. Her future endeavors are poised to make an enduring impact, with ongoing research and leadership contributions that will shape the future of clinical development. Her philanthropic work, such as building a nursery in Uganda, highlights her dedication to global well-being beyond her professional achievements. Dr. Gilaberte continues to inspire the next generation of clinical researchers, ensuring that her legacy of precision, empathy, and patient-first innovation will endure.

 

Publications


📄 Efficacy and Safety of Weekly Calcifediol Formulations (75 and 100 µg) in Subjects with Vitamin D Deficiency: A Phase II/III Randomised Trial

  • Authors: Esteban Jódar-Gimeno, Jose Luis Pérez-Castrillón, Ján Nociar, Michal Lojka, Dimitar Nikolov, Fernando Cereto-Castro, Snežana Novković, Umberto Tarantino, Nadia Mehsen-Cetre, Paula Arranz, Cristina Martínez Ostalé, Aintzane García-Bea, Inmaculada Gilaberte
  • Journal: Nutrients
  • Year: 2024

📄 Comparative inhibition by oral bilastine, parenteral dexchlorpheniramine, and a new bilastine parenteral (i.v. and i.m.) formulation of histamine-induced wheal and flare response: A randomised phase I trial

  • Authors: Coimbra, J., Puntes, M., Molina, P., Arranz, P., Sánchez, C.
  • Journal: European Journal of Pharmaceutical Sciences
  • Year: 2024

📄  Bioequivalence and Safety of Bilastine 20 mg Orodispersible Tablets and Conventional Tablets: A Randomized, Single-Dose, Two-Period Crossover Study in Healthy Volunteers Under Fasting Conditions

  • Authors: Román, M., Ochoa, D., Martin, S., Arranz, P., Sánchez, C.
  • Journal: Drugs in R and D
  • Year: 2024

📄  Disease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn’s Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims Databases

  • Authors: Karki, C., Latremouille-Viau, D., Gilaberte, I., Romdhani, H., Lightner, A.L.
  • Journal: PharmacoEconomics
  • Year: 2023

📄  Follow-up Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel (Mesenchymal Stem Cell Treatment) in Patients With Perianal Fistulizing Crohn’s Disease: ADMIRE-CD Phase 3 Randomized Controlled Trial

  • Authors: Garcia-Olmo, D., Gilaberte, I., Binek, M., Spinelli, A., Panés, J.
  • Journal: Diseases of the Colon and Rectum
  • Year: 2022

 

Rengui Saxu | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Dr. Rengui Saxu | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

China Pharmaceutical University | China                    

Author Profile

Orcid

Early Academic Pursuits 🎓

Dr. Rengui Saxu began his academic journey at Shenyang Medical College, where he pursued a degree in Clinical Medicine Science from 2012 to 2017. During his studies, he completed an internship at Shenyang Central Hospital in 2017, gaining hands-on experience in clinical practice. His academic dedication earned him the National Encouragement Scholarship and the title of Outstanding Graduate, marking his potential as a rising scholar in the field of medicine. Continuing his academic path, Dr. Saxu pursued a Master of Pharmacy Engineering at Tianjin University of Science & Technology from 2017 to 2020. During this time, he took on leadership roles, notably serving as the Head of the Academic Department of the University Graduate Association. His work in pharmacy engineering was recognized with the Zhixing Scholarship for Postgraduate Students.

Professional Endeavors 🏅

Dr. Saxu is currently engaged in advanced research as a Ph.D. candidate in Pharmacology at China Pharmaceutical University (2021-2025). He works under the supervision of Yong Yang, a prominent figure in pharmacological research, and Harvest F. Gu, Chief Scientist at Karolinska Medical School in Sweden. His research spans crucial areas in pharmacology, focusing on drug development and the mechanisms of disease, particularly in relation to diabetes, kidney disease, and cancer.

Contributions and Research Focus 🔬

Dr. Saxu's research contributions are vast, with a focus on pharmacological innovations and therapeutic interventions for diseases like diabetes and cancer. One of his notable patents is a Chinese patent for a method involving selenium-substituted axitinib, which offers anti-tumor applications. His academic publications reflect his deep involvement in cutting-edge research:

  • His studies on asymmetries in adrenal glands and their role in glucocorticoid production provide insights into diabetes-related obesity.
  • He has explored the therapeutic potential of Abelmoschus manihot (L.) in treating diabetic nephropathy via the gut-kidney axis, contributing to the advancement of herbal medicine in disease management.
  • Dr. Saxu has also investigated how Huangkui capsules inhibit aldosterone synthesis in diabetic kidney disease, a promising direction for traditional Chinese medicine.

Accolades and Recognition 🏆

Dr. Saxu's academic excellence has been recognized through numerous prestigious awards:

  • National Encouragement Scholarship
  • Zhixing Scholarship for Postgraduate Students
  • Doctoral Research Incentive Scholarship
  • Outstanding Doctoral Scholarship

These accolades reflect his commitment to research and innovation in the field of pharmacology.

Impact and Influence 🌍

Dr. Saxu's research has had a considerable impact on the medical and pharmacological fields, particularly in the treatment of diabetes and kidney disease. His work on drug therapy and natural compound-based treatments has opened new avenues for understanding and combating complex diseases. His research not only influences medical practices in China but also has international implications, especially in areas related to drug efficacy and safety.

Legacy and Future Contributions 🚀

Dr. Saxu’s future contributions are poised to advance pharmacological research significantly, especially in the areas of cancer therapy and chronic disease management. As a researcher under highly esteemed mentors like Yong Yang and Harvest F. Gu, his ongoing work will likely lead to breakthroughs in targeted therapies and personalized medicine. In the years to come, Dr. Saxu's work will continue to shape the landscape of pharmaceutical sciences, offering hope for more effective and less harmful treatment options. His contributions to medical research, especially in oncology and diabetes, will leave a lasting legacy in global healthcare.

 

Publications


📜 Higher Steroid Production in the Right Adrenal Gland Compared to the Left One in db/db Mice, a Model of Type 2 Diabetic Obesity

  • Authors: Rengui Saxu, Qiming Luo, Yong Yang, Harvest F. Gu
  • Journal: International Journal of Molecular Sciences
  • Year: 2024

📜 Asymmetries of Left and Right Adrenal Glands in Neural Innervation and Glucocorticoids Production

  • Authors: Rengui Saxu, Yong Yang, Harvest F. Gu
  • Journal: International Journal of Molecular Sciences
  • Year: 2023

 

Ylenia Della Rocca | Medicine and Dentistry | Best Researcher Award

Dr. Ylenia Della Rocca | Medicine and Dentistry | Best Researcher Award

University of Chieti | Italy

Author Profile

Scopus

Orcid

🌱 Early Academic Pursuits

Dr. Ylenia Della Rocca’s academic journey began with exceptional achievements in biotechnology. In 2018, she earned her degree in Biotechnology with a perfect score of 110/110 cum laude from the University of L'Aquila. Her thesis, centered on "Hairy Cell Leukemia," set the stage for her future in oncohematological genetics. She continued to excel with a Master’s degree in Medical Biotechnology, again graduating with academic praise. Her research on the HLA-G 3' UTR region in kidney transplantation at the National Research Center solidified her expertise in medical biotechnology.

🏥 Professional Endeavors

Currently, Dr. Della Rocca serves as a Researcher Technologist and Subject Expert in Histology and Embryology at the University of Chieti. Her impressive academic trajectory culminated in a Ph.D. in "Innovative Technologies in Clinical Medicine & Dentistry" in 2024. As part of her doctoral research, she developed a new iPS cell line during her tenure at the University of Barcelona and Josep Carreras Leukaemia Research Institute. Beyond her role as a researcher, Dr. Della Rocca has been a prominent speaker at numerous international conferences, where her work has garnered significant recognition.

🔬 Contributions and Research Focus

Dr. Della Rocca’s research is at the forefront of biotechnology and regenerative medicine. Her completed and ongoing projects include the development of three-dimensional disease models, studies on tissue differentiation, and the establishment of new iPS cell lines. She has also been pivotal in creating innovative models for carcinogenesis research. Her current patent under review—"Pluripotent Stem Cells Induced by Autologous Gingival Stem Cells and Extracellular Vesicles: A Novel Approach for Cardiac Regeneration"—underscores her groundbreaking contributions to stem cell therapies and regenerative medicine.

🏆 Accolades and Recognition

Dr. Della Rocca’s research career has been marked by numerous accolades, including two prestigious awards for her scientific achievements. She has been a Guest Editor for special issues in renowned journals like the International Journal of Molecular Sciences and has served as a Review Editor for Frontiers in Genetics and Frontiers in Cell and Developmental Biology. Her citation index of 10 reflects the growing impact of her research in the scientific community.

🌍 Impact and Influence

Dr. Della Rocca’s work transcends academic research, as evidenced by her collaborations with top universities and research institutes worldwide, including the University of Barcelona, IRCCS Sicily, and the University of Montreal. She is an active member of the Italian Society of Anatomy and Histology and the Sigma Xi Scientific Research Honor Society. Dr. Della Rocca’s commitment to healthcare is further exemplified by her founding of Associazione Sorrisi in Ospedale (A.S.I.O.), a third-sector organization aimed at improving patient care in hospitals.

🔮 Legacy and Future Contributions

As a leader in the fields of stem cells, bioengineering, and regenerative medicine, Dr. Ylenia Della Rocca continues to push the boundaries of scientific knowledge. Her contributions to cell-free therapies and the development of three-dimensional models hold immense promise for future medical applications. With her ongoing work in stem cell regeneration and epigenetic research, Dr. Della Rocca is poised to shape the next frontier of clinical and research tools, leaving a lasting legacy in biotechnology.

 

Publications


📄 Autologous hGMSC-Derived iPS: A New Proposal for Tissue Regeneration
Authors: Ylenia Della Rocca, Francesca Diomede, Fanì Konstantinidou, Valentina Gatta, Liborio Stuppia, Umberto Benedetto, Marco Zimarino, Paola Lanuti, Oriana Trubiani, Jacopo Pizzicannella
Journal: International Journal of Molecular Sciences
Year: 2024


📄 Biological Effects of PMMA and Composite Resins on Human Gingival Fibroblasts: An In Vitro Comparative Study
Authors: Ylenia Della Rocca, Enrico Matteo Traini, Oriana Trubiani, Tonino Traini, Antonella Mazzone, Guya Diletta Marconi, Jacopo Pizzicannella, Francesca Diomede
Journal: International Journal of Molecular Sciences
Year: 2024


 

Jiang hua Yang | Medicine and Dentistry | Best Researcher Award

Dr. Jianghua Yang | Medicine and Dentistry | Best Researcher Award

Yijishan Hospital | China

Author Profile

Scopus

Early Academic Pursuits

Dr. Jianghua Yang began his academic journey in the medical field with a focus on infectious diseases. His foundational studies laid the groundwork for a career dedicated to understanding and combating a variety of infectious diseases. Over the years, Dr. Yang has honed his expertise and developed a deep research interest in several key areas, including tuberculosis, severe fever with thrombocytopenia syndrome, schistosomiasis, and hepatitis.

Professional Endeavors

Dr. Jianghua Yang is currently associated with the Department of Infectious Diseases at Yijishan Hospital of Wannan Medical College in Wuhu, Anhui, China. In his professional role, he has undertaken significant research projects and contributed extensively to the field of infectious diseases. His work is characterized by a commitment to advancing medical knowledge and improving patient outcomes through rigorous scientific inquiry and collaboration with other researchers.

Contributions and Research Focus

Dr. Yang's research spans several critical areas in infectious diseases. His studies on tuberculosis have been published in reputable journals such as "Tuberculosis (Edinb)" and the "International Journal of Infectious Diseases". His work on severe fever with thrombocytopenia syndrome has appeared in the "Journal of Medical Virology" and the "Japanese Journal of Infectious Diseases". Additionally, Dr. Yang has investigated schistosomiasis, with his findings published in "Scientific Reports" and "Journal of Cancer". His research on hepatitis has been featured in the "European Journal of Gastroenterology & Hepatology" and "BMC Gastroenterology". These contributions have not only enhanced the understanding of these diseases but have also provided valuable insights into their diagnosis, treatment, and management.

Accolades and Recognition

Throughout his career, Dr. Yang has received recognition for his impactful research and contributions to the field of infectious diseases. His publications have been cited by peers, reflecting the significance and influence of his work. Dr. Yang's dedication to advancing medical science has earned him respect and acknowledgment within the academic and medical communities.

Impact and Influence

Dr. Yang's research has had a substantial impact on the understanding and treatment of infectious diseases. His work on tuberculosis and severe fever with thrombocytopenia syndrome has informed clinical practices and guided further research in these areas. By elucidating the complexities of diseases such as schistosomiasis and hepatitis, Dr. Yang has contributed to the development of more effective diagnostic and therapeutic strategies, thereby improving patient care and outcomes.

Legacy and Future Contributions

Dr. Jianghua Yang's legacy in the field of infectious diseases is marked by his significant research contributions and his commitment to advancing medical knowledge. As he continues his work, Dr. Yang is poised to make further groundbreaking discoveries that will enhance the understanding of infectious diseases and lead to better health outcomes worldwide. His ongoing research and dedication to scientific excellence will undoubtedly inspire future generations of researchers and healthcare professionals.

 

Notable Publications

Trends of type 2 diabetes with pulmonary tuberculosis patients,2013–2022, and changes after the coronavirus disease 2019 (COVID-19) pandemic 2024 (2)

Construction of an early differentiation diagnosis model for patients with severe fever with thrombocytopenia syndrome and hemorrhagic fever with renal syndrome 2024

Prevalence and impact of viral myocarditis in patients with severe fever with thrombocytopenia syndrome 2024

Clinicopathological characteristics and its association with digestive system tumors of 1111 patients with Schistosomiasis japonica 2023 (1)

A risk prediction model for acute kidney injury in patients with pulmonary tuberculosis during anti-tuberculosis treatment 2022 (4)

 

 

 

 

 

Chansokhon Ngan | Medicine and Dentistry | Best Researcher Award

Mr. Chansokhon Ngan | Medicine and Dentistry | Best Researcher Award

West China Hospital of Sichuan University | China

Author Profile

Orcid

Early Academic Pursuits

Mr. Chansokhon Ngan embarked on his academic journey with a fervent dedication to advancing knowledge in critical care medicine. As a PhD student specializing in Critical Care Medicine at West China Hospital of Sichuan University, he cultivated a strong foundation in research methodologies, data analysis, and clinical practice. His academic pursuits equipped him with the necessary skills to address complex clinical challenges and contribute meaningfully to patient care and medical research.

Professional Endeavors

Throughout his career, Mr. Ngan has been committed to advancing knowledge in critical care medicine through his research endeavors. One of his notable studies, titled "Cardiac index and heart rate as prognostic indicators for mortality in septic shock: A retrospective cohort study from the MIMIC-IV," exemplifies his dedication to excellence in research. Published in Heliyon Journal, this study investigated the relationship between cardiac index (CI), heart rate (HR), and mortality in septic shock patients, utilizing sophisticated data analysis techniques.

Contributions and Research Focus

Mr. Ngan's research focus revolves around critical illnesses, such as septic shock and acute respiratory distress syndrome (ARDS). His contributions to the field include studies on prognostic indicators for mortality in septic shock and predicting the early incidence and stratification of ARDS. Additionally, he is engaged in investigating the application of critical care ultrasound in managing acute respiratory and circulatory dysfunction, aiming to enhance clinical practices and improve patient outcomes.

Accolades and Recognition

Mr. Ngan's dedication to excellence in research has earned him recognition in the medical community. His study on prognostic indicators for mortality in septic shock, published in Heliyon Journal, showcases his commitment to advancing knowledge in critical care medicine. His contributions have been acknowledged for their implications for clinical practice and patient care.

Impact and Influence

Mr. Ngan's research endeavors have made a significant impact on the field of critical care medicine. By investigating prognostic indicators for mortality in septic shock and exploring the application of critical care ultrasound, he has contributed valuable insights that have the potential to improve patient outcomes and enhance clinical practices. His work has influenced the way healthcare providers monitor and manage critical illnesses, leading to more informed decision-making and improved patient care.

Legacy and Future Contributions

As Mr. Ngan continues his academic journey, he remains dedicated to making meaningful contributions to the field of critical care medicine. His research legacy encompasses a commitment to excellence, innovation, and improving patient outcomes. Through his ongoing endeavors, he aims to advance knowledge in critical care medicine, ultimately leaving a lasting impact on the field and paving the way for enhanced clinical practices and patient care.

Notable Publications

Cardiac index and heart rate as prognostic indicators for mortality in septic shock: A retrospective cohort study from the MIMIC-IV database 2024

Yannick Allanore | Medicine and Dentistry | Best Research Article Award

Prof. Yannick Allanore | Medicine and Dentistry | Best Research Article Award

Université Paris Cité | France

Author Profile

Scopus

Early Academic Pursuits

Yannick Allanore commenced his academic journey at Paris Descartes University, obtaining a Master's degree in 1999, followed swiftly by a Medical Doctor certification in 2000. His commitment to specialization in Rheumatology led to a Certification in Rheumatology in 2001. His profound interest in the field culminated in a thesis on "Oxidative stress and systemic sclerosis," earning him a Physician Doctor title in 2004.

Professional Endeavors

His academic tenure unfolded as an Assistant Professor at Paris Descartes University's Rheumatology department at Cochin Hospital from 2005 to 2008. Allanore's research prowess was acknowledged with a Research Habilitation in 2005, focusing on the pathogenesis of systemic sclerosis. Subsequently, he served as a Post-doctoral researcher at INSERM U781 and U1016, delving into the genetic bases and chronic inflammation of systemic sclerosis.

Contributions and Research Focus

Allanore leads a groundbreaking research team at Institut Cochin, delving into pathogenesis and innovative therapies for fibro-inflammatory rheumatic diseases since 2018. His research delves into genetic and pathophysiological aspects of systemic sclerosis, cardio-pulmonary involvement, clinical trials, and endothelial progenitor cells in rheumatic diseases.

Accolades and Recognition

Professor Allanore boasts a substantial publication record, exceeding 480 papers in peer-reviewed journals, showcasing an impressive H-Index of 71. His contributions have earned him memberships in esteemed societies such as the French Rheumatology Society, American College of Rheumatology, and significant roles within EUSTAR and the World Scleroderma Foundation.

Impact and Influence

His leadership roles, including former chairman of EUSTAR and current vice-director of Institut Cochin, testify to his impact on the global rheumatology community. Allanore's multifaceted approach—integrating clinical research, genetic studies, cellular biology, and animal model platforms—underlines his comprehensive influence on understanding and treating chronic inflammatory rheumatic diseases.

Legacy and Future Contributions

Yannick Allanore's legacy lies in his pivotal contributions to unraveling the complexities of systemic sclerosis and related conditions. His leadership in research and academia continues to pave the way for innovative therapies and a deeper comprehension of these debilitating diseases. As vice-director of Institut Cochin, his ongoing dedication promises further advancements in the field of rheumatology.

Notable Publications

Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: a EUSTAR database analysis 2023 (1)

Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital 2023 (2)

Comparison of subcutaneous and oral methotrexate initiation in rheumatoid arthritis in current practice 2023 (1)